Clément Vidal Is Appointed New CEO at eCential

eCential Robotics is pleased to announce the appointment of Clément Vidal as its new Chief Executive Officer. Clément Vidal, an Ecole Polytechnique and Stanford University graduate, has 20 years of experience in the Pharmaceutical and Medical Device industry, especially as CEO of surgical robotics company Endocontrol. Clément will be succeeding Stéphane Lavallée, founder, who will now serve as non-executive Chairman of the Board.

“Through his excellent management of key strategic development programs within eCential Robotics, Clément has proven himself to be not only an amazing leader, but a visionary with a solid understanding of the surgical robotics market,” said Lavallée. “I am most confident that Clément will succeed in taking the company to the next level, with the same passion and commitment to innovation that has always been our hallmark.”

A unique company and product
Founded in 2009, eCential Robotics started its journey with only a handful of visionary engineers to invent the surgical technologies of the future. Working hand-in-hand with leading surgeons around the world, the company developed the first open, unified yet modular and scalable 2D/3D imaging, navigation and robotic guidance system for spine surgery. Recognized with several innovation awards, the company attracted strong funding partners, leading to an initial limited release in Europe with over 10 systems sold and installed. Having received FDA clearance for its platform, the team is now gearing up to develop its activities in the US.

Accelerating activities with implant partners and US customers

“I am honored to take on the role of CEO at such an exciting time for the company,” said Vidal. “The team recently demonstrated its ability to successfully partner with MedTech companies, as well as commercialize our proprietary robotics system by signing a supply contract with a major healthcare group in the United States.”

Under Clément Vidal’s leadership, eCential Robotics will continue to build a culture of excellence, enhance the company’s product portfolio roadmap, develop its commercial activities in the US as well as partner internationally with implant manufacturers, tech companies and research labs to expand the range of Applications available on its unique Open eCential Platform.

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.